Medicare Advantage plans, which cover over 28 million Americans, have seen their star ratings recalculated by the Centers for Medicare and Medicaid Services (CMS) for the second time this year. This move adds more volatility to the program, as plans that receive four out of five stars or better are eligible for bonus payments, which have grown to $16 billion this year.
Why It Matters
The Medicare Advantage star ratings recalculation has significant implications for healthcare providers and patients. The bonus payments, which are tied to the star ratings, can impact the financial stability of healthcare organizations. Additionally, the endorsement of Moderna's mRNA flu vaccine by the FDA advisory panel marks a significant development in the fight against influenza.
Key Numbers
- **28 million: The number of Americans covered by Medicare Advantage plans.
- ****$16 billion:** The amount of bonus payments tied to Medicare Advantage star ratings this year.
- **4/5: The star rating required for Medicare Advantage plans to receive bonus payments.
Background
The 340B drug discount program, which provides discounts to eligible hospitals and healthcare organizations, has been a subject of controversy. Eli Lilly's decision to end discounts to some hospitals that failed to provide claims data is a significant development in this space.
What Experts Say
"The recalculation of Medicare Advantage star ratings adds more uncertainty to the program." — **CMS Official**
"The endorsement of Moderna's mRNA flu vaccine is a significant step forward in the fight against influenza." — **FDA Advisory Panel Member**
Key Facts
- Who: Centers for Medicare and Medicaid Services (CMS), FDA, Eli Lilly
- What: Recalculation of Medicare Advantage star ratings, endorsement of Moderna's mRNA flu vaccine, end of 340B drug discounts to some hospitals
- Impact: Significant implications for healthcare providers and patients
What Comes Next
The implications of these developments will be closely watched in the coming months. As the healthcare landscape continues to evolve, it remains to be seen how these changes will impact patients, providers, and the industry as a whole.